219 related articles for article (PubMed ID: 25633587)
1. Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C.
Pencina MJ; D'Agostino RB; Zdrojewski T; Williams K; Thanassoulis G; Furberg CD; Peterson ED; Vasan RS; Sniderman AD
Eur J Prev Cardiol; 2015 Oct; 22(10):1321-7. PubMed ID: 25633587
[TBL] [Abstract][Full Text] [Related]
2. LDL/apo B ratio predict coronary heart disease in Type 2 diabetes independent of ASCVD risk score: A case-cohort study.
Rabizadeh S; Rajab A; Mechanick JI; Moosaie F; Rahimi Y; Nakhjavani M; Esteghamati A
Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1477-1485. PubMed ID: 33810957
[TBL] [Abstract][Full Text] [Related]
3. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.
Pischon T; Girman CJ; Sacks FM; Rifai N; Stampfer MJ; Rimm EB
Circulation; 2005 Nov; 112(22):3375-83. PubMed ID: 16316964
[TBL] [Abstract][Full Text] [Related]
4. Combined use of apolipoprotein B/apolipoprotein A1 ratio and non-high-density lipoprotein cholesterol before routine clinical lipid measurement in predicting coronary heart disease.
Pan L; Lu G; Chen Z
Coron Artery Dis; 2014 Aug; 25(5):433-8. PubMed ID: 24608795
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein B/apolipoprotein A1 ratio and non-high-density lipoprotein cholesterol. Predictive value for CHD severity and prognostic utility in CHD patients.
Liting P; Guoping L; Zhenyue C
Herz; 2015 Mar; 40 Suppl 1():1-7. PubMed ID: 25374385
[TBL] [Abstract][Full Text] [Related]
6. Low-density lipoprotein cholesterol-to-apolipoprotein B ratio as a potential indicator of LDL particle size and plasma atherogenicity in type 2 diabetes.
Viktorinova A; Malickova D; Svitekova K; Choudhury S; Krizko M
Diabetes Res Clin Pract; 2021 Jun; 176():108858. PubMed ID: 34015391
[TBL] [Abstract][Full Text] [Related]
7. Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events.
Elshazly MB; Nicholls SJ; Nissen SE; St John J; Martin SS; Jones SR; Quispe R; Stegman B; Kapadia SR; Tuzcu EM; Puri R
Am J Cardiol; 2016 Sep; 118(5):647-55. PubMed ID: 27392507
[TBL] [Abstract][Full Text] [Related]
8. Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies.
Joshi PH; Toth PP; Lirette ST; Griswold ME; Massaro JM; Martin SS; Blaha MJ; Kulkarni KR; Khokhar AA; Correa A; D'Agustino RB; Jones SR;
Eur J Prev Cardiol; 2016 Jan; 23(1):41-9. PubMed ID: 25062744
[TBL] [Abstract][Full Text] [Related]
9. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
10. Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence.
Hermans MP; Sacks FM; Ahn SA; Rousseau MF
Cardiovasc Diabetol; 2011 Feb; 10():20. PubMed ID: 21356116
[TBL] [Abstract][Full Text] [Related]
11. Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein Cholesterol.
Sniderman AD; Islam S; McQueen M; Pencina M; Furberg CD; Thanassoulis G; Yusuf S
J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27737874
[TBL] [Abstract][Full Text] [Related]
12. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials.
Robinson JG; Wang S; Jacobson TA
Am J Cardiol; 2012 Nov; 110(10):1468-76. PubMed ID: 22906895
[TBL] [Abstract][Full Text] [Related]
14. Age, Sex, and Cardiovascular Risk Attributable to Lipoprotein Cholesterol Among Chinese Individuals with Coronary Artery Disease: A Case-Control Study.
Wu TT; Zheng YY; Yang YN; Li XM; Ma YT; Xie X
Metab Syndr Relat Disord; 2019 May; 17(4):223-231. PubMed ID: 30720383
[No Abstract] [Full Text] [Related]
15. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
[TBL] [Abstract][Full Text] [Related]
16. Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines.
Sathiyakumar V; Park J; Quispe R; Elshazly MB; Michos ED; Banach M; Toth PP; Whelton SP; Blumenthal RS; Jones SR; Martin SS
Circulation; 2018 Jul; 138(3):244-254. PubMed ID: 29506984
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein B is not superior to non-high-density lipoprotein cholesterol for dyslipidemic classification of glycated hemoglobin-defined diabetic patients.
Xie J; Hu S
Medicine (Baltimore); 2018 Oct; 97(42):e12896. PubMed ID: 30335016
[TBL] [Abstract][Full Text] [Related]
18. Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol.
Ogita M; Miyauchi K; Miyazaki T; Naito R; Konishi H; Tsuboi S; Dohi T; Kasai T; Yokoyama T; Okazaki S; Kurata T; Daida H
Heart Vessels; 2014 Jan; 29(1):35-41. PubMed ID: 23516028
[TBL] [Abstract][Full Text] [Related]
19. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
Lorenzatti AJ; Monsalvo ML; López JAG; Wang H; Rosenson RS
Cardiovasc Diabetol; 2021 Apr; 20(1):94. PubMed ID: 33941192
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease.
Welsh C; Celis-Morales CA; Brown R; Mackay DF; Lewsey J; Mark PB; Gray SR; Ferguson LD; Anderson JJ; Lyall DM; Cleland JG; Jhund PS; Gill JMR; Pell JP; Sattar N; Welsh P
Circulation; 2019 Aug; 140(7):542-552. PubMed ID: 31216866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
